Esperion Therapeutics, Inc.

NewAmsterdam Pharma Company has added more evidence that its CETP inhibitor obicetrapib is effective at lowering low-density lipoprotein cholesterol (LDL-C) in patients at risk of cardiovascular disea

As shown in part one of this series, the chart above shows expected sales differences between 2024 and 2025 grouped by therapeutic category. The leading 10 growth drivers have been singled out – as ha

The first of four Phase III clinical trials testing NewAmsterdam Pharma BV ’s cholesteryl ester transfer protein (CETP) inhibitor obicetrapib for the treatment of high cholesterol has read out positi

Taking Stock Of Expensive Biotech I took the decision recently to take profits from much of my exposure to biotech companies in the exchange-traded funds that are based on the NASDAQ Biotech Index (NB